Ask AI
ProCE Banner Activity

Targeting TROP-2 and TIGIT: Novel Treatment Approaches for Lung Cancer in 2025

Clinical Thought

The evolving roles of TROP-2–targeting ADCs and anti-TIGIT therapies are changing the treatment landscape in lung cancer. Read our thoughts on how you can incorporate these agents into clinical practice as they become available.

Released: September 30, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Disclosure

Primary Author

Benjamin Levy, MD, FASCO: consultant/advisor/speaker: AstraZeneca, DSI, Janssen, Merck, Pfizer.

Helena Yu, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Systimmune, Taiho.